Four Decades for Justice
Maggie Segall is a member of the Antitrust Practice. Her practice focuses on transactional matters, antitrust regulatory approval, government investigations and general antitrust counseling. She has advised a wide variety of clients in diverse industries, including aerospace and aviation, pharmaceuticals, life sciences, consumer products, media, manufacturing and technology.
Ms. Segall has represented clients on antitrust issues in connection with numerous proposed or completed deals. These representations include:
Altra Industrial’s $5 billion acquisition by Regal Rexnord;
RWE AG’s $6.8 billion acquisition of Con Edison Clean Energy Businesses;
ADT’s $1.2 billion equity investment from State Farm;
Micro Focus’s $6 billion acquisition by OpenText Corp;
Global Blood Therapeutics’s $5.4 billion acquisition by Pfizer;
Additionally, Ms. Segall is representing Corteva in antitrust litigation brought by the Federal Trade Commission (FTC) and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive, as well as more than two dozen related putative class actions, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint. She recently was part of the team representing Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history, securing a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
Ms. Segall has been repeatedly recognized for her antitrust work by Chambers USA and The Legal 500 US, including being recommended as a Leading Lawyer for antitrust merger control. She has been named to Crain’s New York Business’s list of “Notable Women in Law,” Bloomberg Law’s “40 Under 40” list and Global Competition Review’s “40 Under 40” list. Who’s Who Legal has also consistently recommended Ms. Segall for her antitrust work, including recently naming her the “Most Highly Regarded Future Leader” in Competition in North America. Benchmark Litigation has named Ms. Segall a “Future Star” and included her on its “40 & Under List,” and Lawdragon has included her on its “500 Leading Litigators in America” list. She was also recently recognized as one of Law360’s “Rising Stars” in Competition and received Euromoney Legal Media Group’s Rising Star Award for “Best in Antitrust/Competition.”
Ms. Segall is a Fellow of the American Bar Foundation and is a member of the International Bar Association’s, American Bar Association’s and the New York State Bar Association’s Antitrust Sections.
Ms. Segall was born in Ann Arbor, Michigan. She received an A.B. magna cum laude from Harvard College in 2003, where she concentrated in History. She received a J.D. cum laude from Harvard Law School in 2008, where she was a member of the Board of Student Advisors and the International Law Journal and the president of Harvard Law School’s wine appreciation society.
Ms. Segall joined Cravath in 2008 and was elected a partner in 2016.
Ms. Segall has represented clients on antitrust issues in connection with numerous proposed or completed deals. These representations include:
Altra Industrial’s $5 billion acquisition by Regal Rexnord;
RWE AG’s $6.8 billion acquisition of Con Edison Clean Energy Businesses;
ADT’s $1.2 billion equity investment from State Farm;
Micro Focus’s $6 billion acquisition by OpenText Corp;
Global Blood Therapeutics’s $5.4 billion acquisition by Pfizer;
Additionally, Ms. Segall is representing Corteva in antitrust litigation brought by the Federal Trade Commission (FTC) and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive, as well as more than two dozen related putative class actions, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint. She recently was part of the team representing Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history, securing a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
Ms. Segall has been repeatedly recognized for her antitrust work by Chambers USA and The Legal 500 US, including being recommended as a Leading Lawyer for antitrust merger control. She has been named to Crain’s New York Business’s list of “Notable Women in Law,” Bloomberg Law’s “40 Under 40” list and Global Competition Review’s “40 Under 40” list. Who’s Who Legal has also consistently recommended Ms. Segall for her antitrust work, including recently naming her the “Most Highly Regarded Future Leader” in Competition in North America. Benchmark Litigation has named Ms. Segall a “Future Star” and included her on its “40 & Under List,” and Lawdragon has included her on its “500 Leading Litigators in America” list. She was also recently recognized as one of Law360’s “Rising Stars” in Competition and received Euromoney Legal Media Group’s Rising Star Award for “Best in Antitrust/Competition.”
Ms. Segall is a Fellow of the American Bar Foundation and is a member of the International Bar Association’s, American Bar Association’s and the New York State Bar Association’s Antitrust Sections.
Ms. Segall was born in Ann Arbor, Michigan. She received an A.B. magna cum laude from Harvard College in 2003, where she concentrated in History. She received a J.D. cum laude from Harvard Law School in 2008, where she was a member of the Board of Student Advisors and the International Law Journal and the president of Harvard Law School’s wine appreciation society.
Ms. Segall joined Cravath in 2008 and was elected a partner in 2016.
American Bar Foundation
American Bar Association
International Bar Association
New York State Bar Association
Benchmark Litigation
Bloomberg Law
Chambers USA
Crain’s New York Business
Global Competition Review
Law360
Lawdragon
The Legal 500 US
Super Lawyers - New York
Who’s Who Legal
Americas Rising Star Awards - Best in Antitrust/Competition, Euromoney Legal Media Group (2018)
Deals & Cases
February 28, 2024
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Deals & Cases
February 06, 2024
On February 6, 2024, altafiber, provider of integrated communications solutions over its fiber‑optic network to residential and business customers in Ohio, Kentucky, and Indiana, and TowerBrook Capital Partners (“TowerBrook”), the New York and London‑based international investment firm, announced that TowerBrook has agreed to acquire CBTS, a leading North American provider of IT solutions and services, from altafiber. Cravath is representing altafiber in connection with the transaction.
Deals & Cases
December 20, 2023
On December 20, 2023, Aon plc (“Aon”), a leading global professional services firm, announced the signing of a definitive agreement to acquire NFP, a leading middle‑market property and casualty broker, benefits consultant, wealth manager and retirement plan advisor, from funds affiliated with NFP’s main capital sponsor, Madison Dearborn Partners, and funds affiliated with HPS Investment Partners. Under the terms of the transaction, Aon will acquire NFP for a total consideration estimated to be $13.4 billion at the time of close, which will be funded by $7 billion of cash and $6.4 billion of Aon stock. Cravath is representing Aon in connection with the transaction.
Deals & Cases
December 18, 2023
On December 18, 2023, ZimVie Inc. (“ZimVie”), a global life sciences leader in the dental and spine markets, announced it has entered into a definitive agreement to sell its spine business to H.I.G. Capital, a leading global alternative investment firm. Under the terms of the agreement, upon the closing of the transaction, ZimVie will receive $375 million in total consideration, comprised of $315 million in cash, subject to certain customary adjustments as set forth in the agreement, and $60 million in the form of a promissory note that will accrue interest at a rate of 10% per annum, compounded semi‑annually, payable in kind. Cravath is representing ZimVie in connection with the transaction.
Deals & Cases
November 21, 2023
On November 20, 2023, Amentum, a portfolio company of Lindsay Goldberg and American Securities, announced a definitive agreement to merge with Jacobs’ Critical Mission Solutions and Cyber and Intelligence businesses, creating a new leader in systems integration and technology solutions. The transaction, which is structured as an all‑stock, Reverse Morris Trust transaction, will result in a publicly traded combined organization with $13 billion in revenue and more than 53,000 employees in 83 countries. Cravath is representing Amentum in connection with the transaction.
Activities & Publications
February 14, 2024
Cravath partners G.J. Ligelis Jr., Alyssa K. Caples, Christopher K. Fargo and Margaret T. Segall co‑authored the U.S. Law & Practice chapter of the fourth edition of Chambers “Investing In… 2024” Guide, which was published in January 2024. The guide, which is part of the publisher’s Global Practice Guides series, examines country‑specific legal issues that arise from foreign direct investment (“FDI”) and cross‑border transactions in the more than 30 jurisdictions covered. The U.S. Law & Practice chapter surveys the legal system and regulatory framework for FDI in the country, analyzing the economic climate, as well as considerations related to mergers and acquisitions, corporate governance, capital markets, antitrust, national security, tax, employment and intellectual property.
Activities & Publications
January 23, 2024
On January 16, 2024, Cravath partner Margaret T. Segall participated in “Perspectives on UK Merger Control in 2024,” an event hosted by Brunswick Group in London. Maggie spoke on a panel entitled “Nobody Does It Better? Lessons from Other Regimes,” which examined approaches taken by different regulatory agencies across the globe and international cooperation between those agencies.
Activities & Publications
December 28, 2023
On December 22, 2023, Cravath prepared a memo for its clients entitled “Merger Guidelines Issued by FTC and DOJ.” The memo examines the Federal Trade Commission and the Department of Justice Antitrust Division’s finalized Merger Guidelines, which modify the draft guidelines released in July and replace the 2010 Horizontal Merger Guidelines and the 2020 Vertical Merger Guidelines. The memo outlines the new guidelines and the additional changes made in finalizing them.
Activities & Publications
November 14, 2023
Cravath partner Margaret T. Segall authored a chapter entitled “Merger Remedies in Dynamic Industries” in Global Competition Review’s “Merger Remedies Guide – Fifth Edition,” which was published on October 25, 2023. The chapter, co‑authored by practice area attorney Nicole M. Peles, reviewed the common types of merger remedies, the characteristics of dynamic industries and challenges posed for traditional merger remedies. The chapter considered the different approaches adopted by antitrust authorities in creating remedies in the technology and pharmaceutical sectors, two rapidly evolving dynamic industries.
Activities & Publications
November 03, 2023
Cravath partners Margaret T. Segall, Nicholas A. Dorsey and G.J. Ligelis Jr. spoke at the International Bar Association’s 2023 Annual Conference, which was held from October 29 to November 3, 2023, in Paris and convened legal professionals from across the globe.
Maggie Segall is a member of the Antitrust Practice. Her practice focuses on transactional matters, antitrust regulatory approval, government investigations and general antitrust counseling. She has advised a wide variety of clients in diverse industries, including aerospace and aviation, pharmaceuticals, life sciences, consumer products, media, manufacturing and technology.
Ms. Segall has represented clients on antitrust issues in connection with numerous proposed or completed deals. These representations include:
Altra Industrial’s $5 billion acquisition by Regal Rexnord;
RWE AG’s $6.8 billion acquisition of Con Edison Clean Energy Businesses;
ADT’s $1.2 billion equity investment from State Farm;
Micro Focus’s $6 billion acquisition by OpenText Corp;
Global Blood Therapeutics’s $5.4 billion acquisition by Pfizer;
Additionally, Ms. Segall is representing Corteva in antitrust litigation brought by the Federal Trade Commission (FTC) and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive, as well as more than two dozen related putative class actions, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint. She recently was part of the team representing Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history, securing a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
Ms. Segall has been repeatedly recognized for her antitrust work by Chambers USA and The Legal 500 US, including being recommended as a Leading Lawyer for antitrust merger control. She has been named to Crain’s New York Business’s list of “Notable Women in Law,” Bloomberg Law’s “40 Under 40” list and Global Competition Review’s “40 Under 40” list. Who’s Who Legal has also consistently recommended Ms. Segall for her antitrust work, including recently naming her the “Most Highly Regarded Future Leader” in Competition in North America. Benchmark Litigation has named Ms. Segall a “Future Star” and included her on its “40 & Under List,” and Lawdragon has included her on its “500 Leading Litigators in America” list. She was also recently recognized as one of Law360’s “Rising Stars” in Competition and received Euromoney Legal Media Group’s Rising Star Award for “Best in Antitrust/Competition.”
Ms. Segall is a Fellow of the American Bar Foundation and is a member of the International Bar Association’s, American Bar Association’s and the New York State Bar Association’s Antitrust Sections.
Ms. Segall was born in Ann Arbor, Michigan. She received an A.B. magna cum laude from Harvard College in 2003, where she concentrated in History. She received a J.D. cum laude from Harvard Law School in 2008, where she was a member of the Board of Student Advisors and the International Law Journal and the president of Harvard Law School’s wine appreciation society.
Ms. Segall joined Cravath in 2008 and was elected a partner in 2016.
Ms. Segall has represented clients on antitrust issues in connection with numerous proposed or completed deals. These representations include:
Altra Industrial’s $5 billion acquisition by Regal Rexnord;
RWE AG’s $6.8 billion acquisition of Con Edison Clean Energy Businesses;
ADT’s $1.2 billion equity investment from State Farm;
Micro Focus’s $6 billion acquisition by OpenText Corp;
Global Blood Therapeutics’s $5.4 billion acquisition by Pfizer;
Additionally, Ms. Segall is representing Corteva in antitrust litigation brought by the Federal Trade Commission (FTC) and 12 state attorneys general challenging certain of its rebate pricing programs as anticompetitive, as well as more than two dozen related putative class actions, centralized in North Carolina federal court, filed in the wake of the FTC’s complaint. She recently was part of the team representing Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history, securing a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
Ms. Segall has been repeatedly recognized for her antitrust work by Chambers USA and The Legal 500 US, including being recommended as a Leading Lawyer for antitrust merger control. She has been named to Crain’s New York Business’s list of “Notable Women in Law,” Bloomberg Law’s “40 Under 40” list and Global Competition Review’s “40 Under 40” list. Who’s Who Legal has also consistently recommended Ms. Segall for her antitrust work, including recently naming her the “Most Highly Regarded Future Leader” in Competition in North America. Benchmark Litigation has named Ms. Segall a “Future Star” and included her on its “40 & Under List,” and Lawdragon has included her on its “500 Leading Litigators in America” list. She was also recently recognized as one of Law360’s “Rising Stars” in Competition and received Euromoney Legal Media Group’s Rising Star Award for “Best in Antitrust/Competition.”
Ms. Segall is a Fellow of the American Bar Foundation and is a member of the International Bar Association’s, American Bar Association’s and the New York State Bar Association’s Antitrust Sections.
Ms. Segall was born in Ann Arbor, Michigan. She received an A.B. magna cum laude from Harvard College in 2003, where she concentrated in History. She received a J.D. cum laude from Harvard Law School in 2008, where she was a member of the Board of Student Advisors and the International Law Journal and the president of Harvard Law School’s wine appreciation society.
Ms. Segall joined Cravath in 2008 and was elected a partner in 2016.
American Bar Foundation
American Bar Association
International Bar Association
New York State Bar Association
Benchmark Litigation
Bloomberg Law
Chambers USA
Crain’s New York Business
Global Competition Review
Law360
Lawdragon
The Legal 500 US
Super Lawyers - New York
Who’s Who Legal
Americas Rising Star Awards - Best in Antitrust/Competition, Euromoney Legal Media Group (2018)
Deals & Cases
February 28, 2024
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Deals & Cases
February 06, 2024
On February 6, 2024, altafiber, provider of integrated communications solutions over its fiber‑optic network to residential and business customers in Ohio, Kentucky, and Indiana, and TowerBrook Capital Partners (“TowerBrook”), the New York and London‑based international investment firm, announced that TowerBrook has agreed to acquire CBTS, a leading North American provider of IT solutions and services, from altafiber. Cravath is representing altafiber in connection with the transaction.
Deals & Cases
December 20, 2023
On December 20, 2023, Aon plc (“Aon”), a leading global professional services firm, announced the signing of a definitive agreement to acquire NFP, a leading middle‑market property and casualty broker, benefits consultant, wealth manager and retirement plan advisor, from funds affiliated with NFP’s main capital sponsor, Madison Dearborn Partners, and funds affiliated with HPS Investment Partners. Under the terms of the transaction, Aon will acquire NFP for a total consideration estimated to be $13.4 billion at the time of close, which will be funded by $7 billion of cash and $6.4 billion of Aon stock. Cravath is representing Aon in connection with the transaction.
Deals & Cases
December 18, 2023
On December 18, 2023, ZimVie Inc. (“ZimVie”), a global life sciences leader in the dental and spine markets, announced it has entered into a definitive agreement to sell its spine business to H.I.G. Capital, a leading global alternative investment firm. Under the terms of the agreement, upon the closing of the transaction, ZimVie will receive $375 million in total consideration, comprised of $315 million in cash, subject to certain customary adjustments as set forth in the agreement, and $60 million in the form of a promissory note that will accrue interest at a rate of 10% per annum, compounded semi‑annually, payable in kind. Cravath is representing ZimVie in connection with the transaction.
Deals & Cases
November 21, 2023
On November 20, 2023, Amentum, a portfolio company of Lindsay Goldberg and American Securities, announced a definitive agreement to merge with Jacobs’ Critical Mission Solutions and Cyber and Intelligence businesses, creating a new leader in systems integration and technology solutions. The transaction, which is structured as an all‑stock, Reverse Morris Trust transaction, will result in a publicly traded combined organization with $13 billion in revenue and more than 53,000 employees in 83 countries. Cravath is representing Amentum in connection with the transaction.
Activities & Publications
February 14, 2024
Cravath partners G.J. Ligelis Jr., Alyssa K. Caples, Christopher K. Fargo and Margaret T. Segall co‑authored the U.S. Law & Practice chapter of the fourth edition of Chambers “Investing In… 2024” Guide, which was published in January 2024. The guide, which is part of the publisher’s Global Practice Guides series, examines country‑specific legal issues that arise from foreign direct investment (“FDI”) and cross‑border transactions in the more than 30 jurisdictions covered. The U.S. Law & Practice chapter surveys the legal system and regulatory framework for FDI in the country, analyzing the economic climate, as well as considerations related to mergers and acquisitions, corporate governance, capital markets, antitrust, national security, tax, employment and intellectual property.
Activities & Publications
January 23, 2024
On January 16, 2024, Cravath partner Margaret T. Segall participated in “Perspectives on UK Merger Control in 2024,” an event hosted by Brunswick Group in London. Maggie spoke on a panel entitled “Nobody Does It Better? Lessons from Other Regimes,” which examined approaches taken by different regulatory agencies across the globe and international cooperation between those agencies.
Activities & Publications
December 28, 2023
On December 22, 2023, Cravath prepared a memo for its clients entitled “Merger Guidelines Issued by FTC and DOJ.” The memo examines the Federal Trade Commission and the Department of Justice Antitrust Division’s finalized Merger Guidelines, which modify the draft guidelines released in July and replace the 2010 Horizontal Merger Guidelines and the 2020 Vertical Merger Guidelines. The memo outlines the new guidelines and the additional changes made in finalizing them.
Activities & Publications
November 14, 2023
Cravath partner Margaret T. Segall authored a chapter entitled “Merger Remedies in Dynamic Industries” in Global Competition Review’s “Merger Remedies Guide – Fifth Edition,” which was published on October 25, 2023. The chapter, co‑authored by practice area attorney Nicole M. Peles, reviewed the common types of merger remedies, the characteristics of dynamic industries and challenges posed for traditional merger remedies. The chapter considered the different approaches adopted by antitrust authorities in creating remedies in the technology and pharmaceutical sectors, two rapidly evolving dynamic industries.
Activities & Publications
November 03, 2023
Cravath partners Margaret T. Segall, Nicholas A. Dorsey and G.J. Ligelis Jr. spoke at the International Bar Association’s 2023 Annual Conference, which was held from October 29 to November 3, 2023, in Paris and convened legal professionals from across the globe.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.